Yamamoto N - Search Results

1

Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib.

Koyama N, Saito K, Nishioka Y, Yusa W, Yamamoto N, Yamada Y, Nokihara H, Koizumi F, Nishio K, Tamura T. Koyama N, et al. Among authors: yamamoto n. BMC Cancer. 2014 Jul 21;14:530. doi: 10.1186/1471-2407-14-530. BMC Cancer. 2014. PMID: 25047123 Free PMC article. Clinical Trial.

2

Phase I/II study of 3-week cycle cisplatin-gemcitabine in advanced non-small cell lung cancer.

Kusaba H, Tamura T, Shimoyama T, Hotta K, Inoue A, Nokihara H, Ueda Y, Akiyama Y, Yamamoto N, Sekine I, Kunitoh H, Ohe Y, Kodama T, Saijo N. Kusaba H, et al. Among authors: yamamoto n. Jpn J Clin Oncol. 2002 Feb;32(2):43-7. doi: 10.1093/jjco/hyf013. Jpn J Clin Oncol. 2002. PMID: 11948227 Clinical Trial.

3

Phase I and pharmacokinetic study of KRN5500, a spicamycin derivative, for patients with advanced solid tumors.

Yamamoto N, Tamura T, Kamiya Y, Ono H, Kondoh H, Shirao K, Matsumura Y, Tanigawara Y, Shimada Y. Yamamoto N, et al. Jpn J Clin Oncol. 2003 Jun;33(6):302-8. doi: 10.1093/jjco/hyg051. Jpn J Clin Oncol. 2003. PMID: 12913085 Clinical Trial.

4

Retrospective analysis of safety and efficacy of low-dose docetaxel 60 mg/m2 in advanced non-small cell lung cancer patients previously treated with platinum-based chemotherapy.

Nakamura Y, Kunitoh H, Kubota K, Sekine I, Yamamoto N, Tamura T, Kodama T, Saijo N. Nakamura Y, et al. Among authors: yamamoto n. Am J Clin Oncol. 2003 Oct;26(5):459-64. doi: 10.1097/01.coc.0000037736.69148.F9. Am J Clin Oncol. 2003. PMID: 14528070

5

Tumor response to chemotherapy: the validity and reproducibility of RECIST guidelines in NSCLC patients.

Watanabe H, Yamamoto S, Kunitoh H, Sekine I, Yamamoto N, Ohe Y, Tamura T, Kodama T, Sugimura K, Saijo N. Watanabe H, et al. Among authors: yamamoto n, yamamoto s. Cancer Sci. 2003 Nov;94(11):1015-20. doi: 10.1111/j.1349-7006.2003.tb01394.x. Cancer Sci. 2003. PMID: 14611681 Free article.

6

Study of paclitaxel and dose escalation of cisplatin in patients with advanced non-small cell lung cancer.

Watanabe H, Yamamoto N, Tamura T, Shimoyama T, Hotta K, Inoue A, Sawada M, Akiyama Y, Kusaba H, Nokihara H, Sekine I, Kunitoh H, Ohe Y, Kodama T, Saijo N. Watanabe H, et al. Among authors: yamamoto n. Jpn J Clin Oncol. 2003 Dec;33(12):626-30. doi: 10.1093/jjco/hyg116. Jpn J Clin Oncol. 2003. PMID: 14769840

7

Treatment of small cell lung cancer in the elderly based on a critical literature review of clinical trials.

Sekine I, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, Saijo N. Sekine I, et al. Among authors: yamamoto n. Cancer Treat Rev. 2004 Jun;30(4):359-68. doi: 10.1016/j.ctrv.2003.12.006. Cancer Treat Rev. 2004. PMID: 15145510 Review.

8

Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.

Takano T, Ohe Y, Kusumoto M, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Tamura T, Kodama T, Saijo N. Takano T, et al. Among authors: yamamoto n, yamamoto s. Lung Cancer. 2004 Jul;45(1):93-104. doi: 10.1016/j.lungcan.2004.01.010. Lung Cancer. 2004. PMID: 15196739 Clinical Trial.

9

Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer.

Sekine I, Noda K, Oshita F, Yamada K, Tanaka M, Yamashita K, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, Sumi M, Saijo N. Sekine I, et al. Among authors: yamamoto n. Cancer Sci. 2004 Aug;95(8):691-5. doi: 10.1111/j.1349-7006.2004.tb03331.x. Cancer Sci. 2004. PMID: 15298734 Free article. Clinical Trial.

10

Three novel single nucleotide polymorphisms in UGT1A10.

Saeki M, Ozawa S, Saito Y, Jinno H, Hamaguchi T, Nokihara H, Shimada Y, Kunitoh H, Yamamoto N, Ohe Y, Yamada Y, Shirao K, Muto M, Mera K, Goto K, Ohmatsu H, Kubota K, Niho S, Kakinuma R, Minami H, Ohtsu A, Yoshida T, Saijo N, Sawada J. Saeki M, et al. Among authors: yamamoto n. Drug Metab Pharmacokinet. 2002;17(5):488-90. doi: 10.2133/dmpk.17.488. Drug Metab Pharmacokinet. 2002. PMID: 15618702 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

6,213 results

Search Page